

Clinical trial underway to test nitric oxide in COVID-19 patients

10 April 2020



study.

"This trial will allow the sickest COVID-19 patients at UAB access to a rescue therapy that may have antiviral benefits in addition to improving the status of lungs," Vibhu Parcha, M.D., research fellow in the UAB Division of Cardiovascular Disease, said in a university news release.

More information: [More Information](#)

Copyright © 2020 [HealthDay](#). All rights reserved.

Doctors at the University of Alabama at Birmingham (UAB) are enrolling patients in an international clinical trial to find out if inhaled nitric oxide benefits those with novel coronavirus (COVID-19) who have severely damaged lungs.

Right now, there are no approved treatments for the illness caused by COVID-19. The severe form of lung failure—[acute respiratory distress syndrome](#)—is the leading cause of death in COVID-19. Nitric oxide has been found to improve [blood flow](#) in areas of the lungs still receiving air, increasing the amount of oxygen in the blood stream.

Along with being used to treat failing lungs, [nitric oxide](#) has been found to have antiviral properties against coronaviruses. That was shown during the 2002 to 2003 severe acute respiratory syndrome outbreak, which was caused by a coronavirus similar to the one that causes COVID-19. Any COVID-19 patient in UAB's intensive care unit who is using a ventilator to breathe may qualify for the

APA citation: Clinical trial underway to test nitric oxide in COVID-19 patients (2020, April 10) retrieved 7 March 2021 from <https://medicalxpress.com/news/2020-04-clinical-trial-underway-nitric-oxide.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.